Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021
29 Juillet 2021 - 1:30PM
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that it will report
the Company’s second quarter 2021 financial results and corporate
highlights on August 5, 2021 at 7:30 a.m. ET.
About Strongbridge
BiopharmaStrongbridge Biopharma is a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs. Strongbridge’s rare endocrine
franchise includes RECORLEV® (levoketoconazole), an adrenal
steroidogenesis inhibitor with a New Drug Application that is
currently under review by the FDA for the treatment of endogenous
Cushing’s syndrome, and veldoreotide extended release, a
pre-clinical next-generation somatostatin analog being investigated
for the treatment of acromegaly and potential additional
applications in other conditions amenable to somatostatin receptor
activation. Both RECORLEV and veldoreotide have received orphan
drug designation from the FDA and the European Medicines Agency.
The company’s rare neuromuscular franchise includes
KEVEYIS® (dichlorphenamide), the first and only FDA-approved
treatment for hyperkalemic, hypokalemic, and related variants of
primary periodic paralysis. KEVEYIS has orphan drug exclusivity in
the United States.
Contacts:
Corporate and Media RelationsElixir Health
Public RelationsLindsay Rocco+1
862-596-1304lrocco@elixirhealthpr.com
Investor RelationsSolebury TroutMike Biega+1
617-221-9660mbiega@soleburytrout.com
Strongbridge Biopharma (NASDAQ:SBBP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Strongbridge Biopharma PLC (NASDAQ): 0 recent articles
Plus d'articles sur